1. Scrip
  2. >>New Products

Pfizer Expands In Breast Cancer With Talazoparib Approval

 
• By Mary Jo Laffler

The PARP inhibitor, acquired with Medivation, will launch in a field where Pfizer already has commercial experience through its CDK4/6 inhibitor Ibrance. 

Breast Cancer Awareness: Microscopic image (photomicrograph) of core biopsy for infiltrating (invasive) ductal carcinoma, detected by screening mammogram. H & E stain.

The US FDA approval of Pfizer Inc.’s PARP inhibitor Talzenna (talazoparib) for BRCA-mutated breast cancer gives Pfizer another launch in a cancer where it already has extensive experience with its blockbuster Ibrance.

Approved for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, Ibrance (palbociclib) entered the market in 2015 and has been...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

Pipeline Watch: Eleven Approvals And ADA Readouts Dominate

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Empty Promises: Five Drugs That Fell Short Of Their Sales Forecasts

 
• By Edwin Elmhirst

Many assets underperform their pre-launch sales predictions, which can be disastrous to their developers and marketers. In this article, Scrip highlights several historic examples and the factors that influenced their poorer-than-expected performance.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

Bluebird Builds Out Leadership Team Under Private Equity Ownership

 
• By Jessica Merrill

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.